Tranexamic Acid for Alloplastic Breast Reconstruction
Primary Purpose
Hematoma Postoperative, Breast Cancer, Tranexamic Acid
Status
Not yet recruiting
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Tranexamic acid
Normal Saline
Sponsored by
About this trial
This is an interventional treatment trial for Hematoma Postoperative focused on measuring Alloplastic Breast Reconstruction
Eligibility Criteria
Inclusion Criteria:
- Are 18 years or older;
- Are undergoing one- or two-stage bilateral alloplastic breast reconstruction immediately after bilateral mastectomy at either Hamilton Health Sciences or St. Joseph's Hospital Hamilton.
Exclusion Criteria:
- Taking therapeutic anticoagulation;
- Taking antiplatelet drugs;
- Pregnant or breast feeding;
- Allergic to TXA;
- Cannot provide informed consent;
- Alloplastic reconstruction is not performed immediately after mastectomy;
- Have a documented coagulopathy or bleeding disorder, acquired disturbances of colour vision, subarachnoid hemorrhage, hematuria, irregular menstrual bleeding, or seizure disorder.
Sites / Locations
- St. Joseph's Healthcare, King Campus
- St. Joseph's Healthcare, Charlton Campus
- Juravinski Hospital, Hamilton Health Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Tranexamic Acid
Normal Saline
Arm Description
3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
40 mL topical of 0.9% normal saline
Outcomes
Primary Outcome Measures
Hematoma
Incidence rate of hematoma
Seroma
Incidence rate of seroma
Secondary Outcome Measures
Drain output
Total drain output (mL) at 24 hours
Days with drains
Total number of days drains in situ with standard discharge criteria
Reoperation rate
Number of repeat operations required for patient related to complication
Reintervention rate
Rate of subsequent interventions including aspiration, repeat drain insertion or other
Imaging findings
Ultrasound findings of hematoma or seroma, if applicable
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04918589
Brief Title
Tranexamic Acid for Alloplastic Breast Reconstruction
Official Title
Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events.
In this randomized control trial (RCT) assessing TXA use in alloplastic breast reconstruction, one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.
Detailed Description
The primary objective of this study is to investigate the use of topical application of tranexamic Acid (TXA) to the surgical wound as a means to decrease hematoma formation compared to placebo in patients undergoing alloplastic breast reconstruction. This project is designed as a single-center RCT to evaluate the effectiveness of topical TXA in this patient population.
If enrolled in this study, patients individual breasts will be randomly assigned to one of two treatment groups for to apply to the wound before it is closed.
One breast will have an intravenous form of TXA applied topically to the surgical site. The other will be have a topical normal saline solution applied to the wound before closure (a placebo).
The patients will have the standard number of drains and postoperative instructions for breast reconstruction. They will follow-up at two weeks time in clinic for assessment, and emergency room visits will be also be evaluated. Standard of care will be practiced with respect to all procedures and visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematoma Postoperative, Breast Cancer, Tranexamic Acid
Keywords
Alloplastic Breast Reconstruction
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo).
Intervention: Topical application of 3 grams of tranexamic acid (30 mL of 100 mg/mL) diluted in 10 mL of normal saline in the breast.
Placebo: Topical application of 40 mL of 0.9% normal saline to the breast.
Masking
ParticipantCare Provider
Masking Description
Patients will be randomized on the REDCap system. Their assignment will be made available to research team member, which will be preparing syringes with either TXA or placebo.
Allocation
Randomized
Enrollment
106 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Tranexamic Acid
Arm Type
Experimental
Arm Description
3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
Arm Title
Normal Saline
Arm Type
Placebo Comparator
Arm Description
40 mL topical of 0.9% normal saline
Intervention Type
Drug
Intervention Name(s)
Tranexamic acid
Other Intervention Name(s)
TXA
Intervention Description
3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
Intervention Type
Drug
Intervention Name(s)
Normal Saline
Other Intervention Name(s)
NS
Intervention Description
40 mL topical of 0.9% normal saline
Primary Outcome Measure Information:
Title
Hematoma
Description
Incidence rate of hematoma
Time Frame
2 weeks
Title
Seroma
Description
Incidence rate of seroma
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Drain output
Description
Total drain output (mL) at 24 hours
Time Frame
24 hours
Title
Days with drains
Description
Total number of days drains in situ with standard discharge criteria
Time Frame
2 weeks
Title
Reoperation rate
Description
Number of repeat operations required for patient related to complication
Time Frame
2 weeks
Title
Reintervention rate
Description
Rate of subsequent interventions including aspiration, repeat drain insertion or other
Time Frame
2 weeks
Title
Imaging findings
Description
Ultrasound findings of hematoma or seroma, if applicable
Time Frame
2 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Are 18 years or older;
Are undergoing one- or two-stage bilateral alloplastic breast reconstruction immediately after bilateral mastectomy at either Hamilton Health Sciences or St. Joseph's Hospital Hamilton.
Exclusion Criteria:
Taking therapeutic anticoagulation;
Taking antiplatelet drugs;
Pregnant or breast feeding;
Allergic to TXA;
Cannot provide informed consent;
Alloplastic reconstruction is not performed immediately after mastectomy;
Have a documented coagulopathy or bleeding disorder, acquired disturbances of colour vision, subarachnoid hemorrhage, hematuria, irregular menstrual bleeding, or seizure disorder.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Minh Huynh, MD
Phone
9055221155
Email
minh.huynh@medportal.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronen Avram, MD, FRCSC
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Joseph's Healthcare, King Campus
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8G 5E4
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark McRae, MD, FRCSC
Facility Name
St. Joseph's Healthcare, Charlton Campus
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophoceles Voineskos, MD, FRCSC
Facility Name
Juravinski Hospital, Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 1C3
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronen Avram, MD, FRCSC
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22611164
Citation
Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012 May 17;344:e3054. doi: 10.1136/bmj.e3054.
Results Reference
background
PubMed Identifier
21048170
Citation
Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.
Results Reference
background
PubMed Identifier
10694619
Citation
De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80. doi: 10.1016/s0022-5223(00)70139-5.
Results Reference
background
PubMed Identifier
22202494
Citation
Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother. 2012 Jan;46(1):97-107. doi: 10.1345/aph.1Q383. Epub 2011 Dec 27.
Results Reference
background
PubMed Identifier
25471907
Citation
Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG, Perez-Chrzanowska H, Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014 Dec 3;96(23):1937-44. doi: 10.2106/JBJS.N.00060.
Results Reference
background
PubMed Identifier
23541868
Citation
Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty. J Arthroplasty. 2013 Aug;28(7):1080-3. doi: 10.1016/j.arth.2012.11.016. Epub 2013 Mar 28.
Results Reference
background
PubMed Identifier
25450009
Citation
Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014 Dec;21(6):987-93. doi: 10.1016/j.knee.2014.09.010. Epub 2014 Oct 23.
Results Reference
background
PubMed Identifier
31187540
Citation
Knight H, Banks J, Muchmore J, Ives C, Green M. Examining the use of intraoperative tranexamic acid in oncoplastic breast surgery. Breast J. 2019 Sep;25(5):1047-1049. doi: 10.1111/tbj.13409. Epub 2019 Jun 11. No abstract available.
Results Reference
background
PubMed Identifier
16996422
Citation
Pinsolle V, Grinfeder C, Mathoulin-Pelissier S, Faucher A. Complications analysis of 266 immediate breast reconstructions. J Plast Reconstr Aesthet Surg. 2006;59(10):1017-24. doi: 10.1016/j.bjps.2006.03.057. Epub 2006 Jun 5.
Results Reference
background
PubMed Identifier
24436188
Citation
Nelson JA, Fischer JP, Grover R, Cleveland E, Erdmann-Sager J, Serletti JM, Wu LC. The impact of anemia on microsurgical breast reconstruction complications and outcomes. Microsurgery. 2014 May;34(4):261-70. doi: 10.1002/micr.22202. Epub 2013 Nov 4.
Results Reference
background
PubMed Identifier
22689664
Citation
Megson M. Traumatic subcutaneous haematoma causing skin necrosis. BMJ Case Rep. 2011 Jul 20;2011:bcr0520114273. doi: 10.1136/bcr.05.2011.4273.
Results Reference
background
PubMed Identifier
32243320
Citation
Rogoff H, Marquez JE, Ghosh K, Jou C, McAuliffe P, Rathi S, Monroig K, Medrano C, Marmor WA, Ferrier A, Kapadia K, Klein G, Huston TL, Ganz J, Dagum AB, Khan S, Bui D. Clinical Outcomes After Hematoma Development: A Study of 627 Tissue Expander Breast Reconstructions. Ann Plast Surg. 2020 Jul;85(S1 Suppl 1):S63-S67. doi: 10.1097/SAP.0000000000002343.
Results Reference
background
Learn more about this trial
Tranexamic Acid for Alloplastic Breast Reconstruction
We'll reach out to this number within 24 hrs